New Delhi, Sept. 23 -- The Supreme Court's sharp questioning over the pricing of essential cancer medicines has brought a deeply troubling problem back into focus: the distance between the price of a medicine and what a patient ultimately pays. The court was told of a cancer drug carrying a maximum retail price of '27,000 even though it was supplied to retailers for about '2,700. Whatever the eventual findings, a tenfold gap of this kind demands regulatory scrutiny. Cancer treatment is not an ordinary consumer purchase in which buyers can postpone spending, shop around or walk away. Patients and families make decisions under extraordinary emotional and financial pressure, often while navigating surgery, diagnostics, hospital bills and loss of income. In such circumstances, opaque pricing can turn illness into a financial catastrophe. India has an important system of price regulation through the Drugs (Prices Control) Order and the National Pharmaceutical Pricing Authority, which fixes ceiling prices for scheduled formulations. Yet the controversy underlines a larger weakness: substantial parts of the pharmaceutical market remain outside direct ceiling-price regulation, leaving room for large differences between supply prices and printed MRPs.
The answer cannot be indiscriminate price controls across the pharmaceutical sector. Drug development, manufacturing, distribution, storage and pharmacovigilance carry legitimate costs, while companies require incentives to invest in new therapies. India also needs a competitive pharmaceutical industry capable of expanding access to innovative treatments. The regulatory challenge is therefore to distinguish legitimate costs and reasonable returns from excessive margins that bear little relationship to value added along the supply chain. That requires transparency. For essential and high-cost medicines, regulators should be able to examine the movement of a drug from manufacturer or importer to distributor, retailer, hospital and patient. Trade margins, discounts and institutional procurement prices should be visible enough to identify extraordinary mark-ups. Hospitals and pharmacies should also provide patients with clearer information about lower-cost equivalents wherever medically appropriate. Competition works only when consumers possess meaningful information; in healthcare, that imbalance is particularly severe because patients depend heavily on doctors, hospitals and pharmacies to guide their choices.
The larger issue is affordability. A medicine may exist, be approved and be widely available, yet remain effectively inaccessible if its price pushes a household towards debt or forces treatment to be abandoned. Cancer exposes this contradiction with particular cruelty because treatment can be prolonged and involve multiple drugs over several cycles. India therefore needs a pricing framework that protects innovation while recognising that essential medicines occupy a special category of public interest. The government should strengthen monitoring of unusually high margins, periodically review medicines covered by price controls, encourage quality generics and biosimilars, and ensure enforcement keeps pace with new therapies and market practices. Greater public procurement and negotiated purchasing can further reduce costs without undermining supply. The Supreme Court's intervention should become an opportunity for systemic reform rather than another temporary controversy. In healthcare, transparency is not merely good market practice. When a patient's survival may depend on purchasing a medicine immediately, fair pricing becomes a question of access, dignity and justice.
Published by HT Digital Content Services with permission from Millennium Post.